Reperfusion injury during myocardial infarction accounts for approximately half of final infarct size. for clinical benefit. However, despite 5 decades of research focusing on mechanisms underlying reperfusion damage almost, there are no clinically significant therapies focusing on this stage of ischemia/reperfusion (I/R) damage. Rather, all our therapies C medicines, products, and early reperfusion C focus […]